PATENT CLAIM ANALYSIS

Application Number: 16135593
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-02
Patent Classification: ["548", "240000"]

Abstract:
This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Claim (Index 22):
The compound according to  claim 21 , wherein each of G 1 , G 2 , G 3  and G 4  is independently selected from N; NR c3 ; O; CHR c3 ; and CR c3 ; and form with the dotted lines one of the cycles having one of the structural formula (Ic), (IIc), (IIIc), (IVc), or (Vc):

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.88235
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14060563', '15215750', '13993723', '13993756', '13377505']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8868358730197206
- 35 USC 102 Novelty (BERT): 0.5970362727400595
- Combined Prediction Score: 0.8578559129917545
- Mean Citation Score: 683.32623
- Max Citation Score: 725.93085
- Similarity Product: 434.84541338334384

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test